Topical tacrolimus shows promise against persistent subepithelial infiltrates
- Posted on: Oct 8 2021
- Leave a response
This case series assessed the efficacy and safety of topical tacrolimus for subepithelial infiltrates (SEIs) due to adenoviral keratoconjunctivitis (AKC) persisting at least 2 years after treatment.
Source: AAO
Posted in: Uncategorized